| Literature DB >> 34970243 |
Lin Zhao1, Jing Han1, Jiaqi Liu1, Kechen Fan1, Tianjie Yuan1, Ju Han1, Liangliang Chen1, Sen Zhang1, Ming Zhao1, Jinao Duan1.
Abstract
Natural flavonoids, formononetin and ononin, possess antioxidant, antibacterial, anti-inflammatory and neuroprotective effects. Many complications caused by SARS-CoV-2 make patients difficult to recover. Flavonoids, especially formononetin and ononin, have the potential to treat SARS-CoV-2 and improve myocardial injury. However, their poor water solubility, poor oral absorption, high toxicity, and high-cost purification limit industrial practical application. Succinylation modification provides a solution for the above problems. Formononetin-7-O-β-(6″-O-succinyl)-D-glucoside (FMP), a new compound, was succinyl glycosylated from formononetin by the organic solvent tolerant bacteria Bacillus amyloliquefaciens FJ18 in a 10.0% DMSO (v/v) system. The water solubility of the new compound was improved by over 106 times compared with formononetin, which perfectly promoted the application of formononetin and ononin. The conversion rate of formononetin (0.5 g/L) was almost 94.2% at 24 h, while the yield of formononetin-7-O-β-(6″-O-succinyl)-D-glucoside could achieve 97.2%. In the isoproterenol (ISO)-induced acute ischemia mice model, the myocardial injury was significantly improved with a high dose (40 mg/kg) of formononetin-7-O-β-(6″-O-succinyl)-D-glucoside. The lactate dehydrogenase level was decreased, and the catalase and superoxide dismutase levels were increased after formononetin-7-O-β-(6″-O-succinyl)-D-glucoside treatment. Thus, formononetin-7-O-β-(6″-O-succinyl)-D-glucoside has high water solubility, low toxicity, and shows significant antimyocardial ischemia effects.Entities:
Keywords: Bacillus amyloliquefaciens FJ18; acute ischemic injury; biotransformation; formononetin; succinyl ononin
Year: 2021 PMID: 34970243 PMCID: PMC8712702 DOI: 10.3389/fmicb.2021.786464
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
The severity of histological changes.
| Score | Severity of histological changes |
| 0 | Normal |
| 1 | Minimal |
| 2 | Mild |
| 3 | Moderate |
| 4 | Moderately severe |
| 5 | Severe |
1H (300 MHz) and 13C (75 Hz) NMR data of formononetin-7-O-β-(6″-O-succinyl)-D-glucoside in DMSO-d6.
| Position | δ13X | δ1H (J in Hz) |
| 2 | 153.6 | 8.39 (1H, s) |
| 3 | 124 | |
| 4 | 174.7 | |
| 5 | 127 | 8.07 (1H, d.8.9) |
| 6 | 115.6 | 7.15 (1H, dd, 8.9, 2.4) |
| 7 | 161.2 | |
| 8 | 103.5 | 7.24 (1H, d, 2.3) |
| 9 | 157 | |
| 10 | 118.6 | 7.52 (2H, d.8.6) |
| 1′ | 123.4 | 7.00 (2H, d, 8.6) |
| 2′ | 130.1 | |
| 3′ | 113.7 | 7.00 (2H, d, 8.6) |
| 4′ | 159.1 | 7.52 (2H, d.8.6) |
| 5′ | 113.7 | 5.15 (1H, d, 7.4) |
| 6′ | 130.1 | |
| 1″ | 99.8 | 5.15 (1H, d, 7.4) |
| 2″ | 73.1 | |
| 3″ | 76.6 | |
| 4″ | 69.9 | |
| 5″ | 74 | |
| 6″ | 63.6 | 4.42 (1H, dd, 11, 2.4), 4.04 |
| 1″′ | 172 | (1H, dd, 11, 7.2) |
| 2″′ | 28.7 | |
| 3″′ | 28.7 | 2.47–2.57 (4H, m) |
| 4″′ | 173.4 | 2.47–2.57 (4H, m) |
| OCH3 | 55.2 | 3.39 (3H, s) |
FIGURE 1Effects of the different doses of formononetin, ononin, and formononetin-7-O-β-(6″-O-succinyl)-D-glucoside (FMP) on the growth of cardiac myocytes H9C2 (n = 10).
FIGURE 2Effect of FMP on LDH activity in the serum of iso-induced myocardial ischemia mice (##p < 0.01 vs. control group; **p < 0.01; *p < 0.05 vs. model group).
FIGURE 3Effect of FMP on SOD activity in the serum of iso-induced myocardial ischemia mice (##p < 0.01 vs. control group; ***p < 0.001, **p < 0.01, *p < 0.05 vs. model group).
FIGURE 4Effect of FMP on CAT activity in the serum of iso-induced myocardial ischemia mice (#p < 0.05 vs. control group; *p < 0.05 vs. model group).
Effects of formononetin-7-O-β-(6″-O-succinyl)-D-glucoside (FMP) on SOD, LDH and CAT activities in serum of mice with myocardial ischemia (, n = 10).
| Groups | Dose (mg⋅kg–1) | SOD (U ml–1) | CAT (U ml–1) | LDH (U L) |
| Blank control | – | 0.89 ± 0.01 | 28.5 ± 4.6 | 62 ± 20 |
| Model | – | 0.76 ± 0.01## | 12.3 ± 2.4# | 144 ± 28## |
| Propranolol | 20 | 0.91 ± 0.06* | 18.8 ± 6.5 | 58 ± 13** |
| Formononetin | 20 | 0.96 ± 0.03** | 17.1 ± 2.4 | 79 ± 22* |
| Ononin | 20 | 0.95 ± 0.02** | 16.8 ± 2.1 | 75 ± 24 |
| Low-dose FMP | 10 | 0.94 ± 0.02** | 17.1 ± 2.7 | 120 ± 23 |
| Medium-dose FMP | 20 | 1.00 ± 0.08*** | 23.2 ± 5.9 | 91 ± 4 |
| High-dose FMP | 40 | 1.12 ± 0.10*** | 26.7 ± 1.8* | 62 ± 12** |
FIGURE 5Effect of FMP on the pathomorphology of myocardial tissue. (A) Blank control group, (B) model group, (C) positive drug group, (D) glycogen group, (E) low-dose FMP, (F) medium-dose FMP, and (G) high-dose FMP.